Hologic, Inc. HOLX
Set alert
At close · Apr 7
After hours · Apr 7, 4:00 PM ET
52-week range unavailable
- YTD
- +2.04%
- 1 year
- +24.06%
- Open
- 76.01
- Prev close
- 76.01
- Mkt cap
- 16.97B
- Vol
- 101.96M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 76.01
- High
- 76.01
- Forward P/E
- 15.64
- Beta
- 0.70
- Short ratio
- 2.78
- Inst. own
- 96.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 7, 2026
- 50-d avg
- 75.31
- 200-d avg
- 71.65
- 1y target
- 76.67
3M chart
Events in this range
- Jan 12, 2026Downgrade: Argus Research · Buy → Hold
- Jan 29, 2026Earnings: —; estimate 1.09; surprise —%
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 19, 2026 | 7 months ago |
| SMA: Bullish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| SMA: Bearish | Mar 13, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 11, 2026 | 7 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 20, 2026 | 9 months ago |
Key statistics
- Market cap
- 16.97B
- Enterprise value
- 17.12B
- Trailing P/E
- 31.54
- Forward P/E
- 15.64
- PEG ratio
- 0.00
- Price / sales
- 4.11
- Price / book
- 3.23
- EPS (TTM)
- 2.41
- Beta
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 13.18%
- Revenue (TTM)
- 4.13B
- Revenue growth
- 2.50%
- Free cash flow
- 848.61M
- Total cash
- 2.37B
- Total debt
- 2.52B
- Return on equity
- 10.86%
- Shares outstanding
- 223.24M
- Short % of float
- 3.66%
- 50-day average
- 75.31
- 200-day average
- 71.65
Analyst view
Consensus: hold
- Target (low)
- 76.00
- Target (mean)
- 76.67
- Target (high)
- 78.00
- Strong buy0
- Buy0
- Hold15
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 1.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 1, 2026 | 1.09 | — | — | — |
| Jan 29, 2026 | Dec 1, 2025 | 1.09 | — | — | — |
| Nov 3, 2025 | Sep 1, 2025 | 1.10 | — | — | — |
| Jul 30, 2025 | Jun 1, 2025 | 1.05 | — | — | — |
| May 1, 2025 | Mar 1, 2025 | 1.02 | — | — | — |
| Feb 5, 2025 | Dec 1, 2024 | 1.02 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 12, 2026 | Argus Research | down | Buy | Hold |
| Jan 5, 2026 | Evercore ISI Group | down | Outperform | In-Line |
| Nov 11, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 23, 2025 | Mizuho | down | Outperform | Neutral |
| Oct 22, 2025 | Raymond James | down | Outperform | Market Perform |
| Oct 22, 2025 | Stephens & Co. | down | Overweight | Equal-Weight |
About Hologic, Inc.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analysis software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology systems; and breast conserving surgery products. In addition, the company provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system. The company sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- hologic.com
News
- Hologic Signs Definitive Agreement to Acquire Reveal Genomics
- Blackstone, TPG seek over $4 billion for Hologic's surgical unit, FT says
- Hologic's New Sustainability Report Marks 40 Years of Impact
- Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology
- OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay
- New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers
- Hologic Goes Private In $18 Billion Blackstone, TPG Acquisition
- Blackstone and TPG Complete Acquisition of Hologic
- Hologic Target of Unusually Large Options Trading (NASDAQ:HOLX)
- Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600
Your note
Sign in to keep a note on HOLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON ERIK S | Officer | Stock Award(Grant) | Nov 10, 2024 | 23,621 |
| GRIFFIN JOHN M | General Counsel | Stock Award(Grant) | Nov 10, 2024 | 183,634 |
| LIDDY ANNE M | General Counsel | Stock Award(Grant) | Nov 9, 2025 | 28,574 |
| MACMILLAN STEPHEN P | Chief Executive Officer | Stock Award(Grant) | Nov 9, 2025 | 2,577,540 |
| MCBRIDE-WENDELL AMY A. | Director | Stock Award(Grant) | Feb 25, 2026 | 25,784 |
| MITCHELL ESSEX D | Chief Operating Officer | Stock Award(Grant) | Nov 9, 2025 | 78,952 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 11.69% | 26,089,403 | 1.98B | Dec 30, 2025 |
| Blackrock Inc. | 9.90% | 22,098,417 | 1.68B | Dec 30, 2025 |
| State Street Corporation | 4.42% | 9,875,663 | 750.65M | Dec 30, 2025 |
| Manufacturers Life Insurance Co. | 4.23% | 9,441,848 | 717.67M | Dec 30, 2025 |
| HBK Investments L P | 3.76% | 8,400,000 | 638.48M | Dec 30, 2025 |
| T. Rowe Price Investment Management, Inc. | 2.66% | 5,932,301 | 450.91M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 7,008,595 | 532.72M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.51% | 5,612,448 | 426.60M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 5,057,952 | 384.45M | Dec 30, 2025 |
| Victory Portfolios-Victory Sycamore Established Value Fund | 1.80% | 4,020,000 | 305.56M | Dec 30, 2025 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 1.46% | 3,261,412 | 247.90M | Dec 30, 2025 |
| -Price (T.Rowe) U.S. Mid-Cap Growth Equity Trust | 1.32% | 2,950,500 | 224.27M | Sep 29, 2025 |